… GJLA van Leenders has served on the advisory board for Roche, and received company
speaker honorarium from Astellas and research grants from Roche and AstraZeneca. Professor …

… von der Thüsen d , Carolien HM van Deurzen d , Linetta B. Koppert f , Geert JLH van
Leenders d , Patricia C. Ewing-Graham d , Helena C. van Doorn ORCID logo g , Clemens MF …

… Author links open overlay panel Geert JLH van Leenders a , Jack A … G Van Leenders, B
Van Balken, T Aalders, C Hulsbergen-van de Kaa, D Ruiter, J … GJ Van Leenders, JA Schalken …

Prostate cancer (PCa) is the most frequent male malignancy and the second most common
cause of cancer-related death in Western countries. Current clinical and pathological …

Purpose : The identification of clinically insignificant prostate cancer could help avoid
overtreatment. Current criteria for insignificant prostate cancer use a tumor volume threshold of …

… Author contributions: Bas WG van Rhijn had full access to all the data in the study and
takes responsibility for the integrity of the data and the accuracy of the data analysis. …

The progression of carcinomas is associated with the loss of epithelial morphology and a
concomitant acquisition of a more mesenchymal phenotype, which in turn is thought to …

… van Leenders et al 58 showed that reducing the GG by one point if no invasive cribriform
or IDC were present at biopsy led to better discriminative value of the GG for cancer-specific …

PURPOSE: To evaluate which parameters of dynamic magnetic resonance (MR) imaging
and T2 relaxation rate would result in optimal discrimination of prostatic carcinoma from …

PURPOSE: To update the analysis of the Dutch dose-escalation trial of radiotherapy for
prostate cancer. PATIENTS AND METHODS: A total of 669 patients with localized prostate …